Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Page 1
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
Clin Cancer Res. 2010 Jan 15;16(2):664-72. doi: 10.1158/1078-0432.CCR-09-2308. Epub 2010 Jan 12.
Clin Cancer Res. 2010.
PMID: 20068097
Free PMC article.
Clinical Trial.
Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.
Sarosy GA, Hussain MM, Seiden MV, Fuller AF, Nikrui N, Goodman A, Minasian L, Reed E, Steinberg SM, Kohn EC.
Sarosy GA, et al.
Cancer. 2010 Mar 15;116(6):1476-84. doi: 10.1002/cncr.24861.
Cancer. 2010.
PMID: 20091841
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite